Systematic Review of the Economic Burden of Pulmonary Arterial Hypertension

Gu, Shi-Jian; Hu, Huimei; Dong, Hengjin

doi:10.1007/s40273-015-0361-0

Cited by 29 publications

(32 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The mean, annual, total direct healthcare costs of Group 3 PH patients to payers were $44,732 (approximately $3,728 per month). Other studies have estimated the economic burden of Group 1 PH (PAH) patients and of Group 4 PH (CTEPH) patients using large claims databases [9–16]. Differences in data sources, eligibility criteria, methodology, and analytical methods among studies limit a direct comparison.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Healthcare burden of pulmonary hypertension owing to lung disease and/or hypoxia

et al. 2017

View full text Add to dashboard Cite

BackgroundGroup 3 pulmonary hypertension (PH) encompasses PH owing to lung diseases and/or hypoxia. Treatment patterns, healthcare resource use, and economic burden to US payers of Group 3 PH patients were assessed.MethodsThis retrospective observational study extracted data from July 1, 2010 to June 30, 2013 from two Truven Health Analytics MarketScan databases. Adult Group 3 PH patients were identified based on claims for PH (ICD-9-CM 416.0/416.8), a related lung disease, and an echocardiogram or right heart catheterization (RHC). The index date was the date of the first PH claim; data were collected for 12 months pre- and post-index. A difference-in-difference approach using generalized estimating equations was done to account for baseline differences.ResultsGroup 3 PH patients (n = 2,236) were matched 1:1 to controls on lung disease. PH patients had higher all-cause resource utilization and annual healthcare costs ($44,732 vs. $7,051) than controls. Costs were driven by inpatient admissions (35.4% of total costs), prescriptions (33.0%), and outpatient care (26.5%). Respiratory-related costs accounted for 11.4% of post-index annual costs for PH patients. PH diagnosis was not confirmed in the majority of PH patients (<7% RHC use) but nevertheless, 22% of PH patients post-index had claims for drugs approved for the treatment of pulmonary arterial hypertension (PAH).ConclusionsGroup 3 PH poses a significant clinical and economic burden. Given the low use of RHC and the prevalence of PAH-indicated prescriptions that are not currently approved for Group 3 PH, this study suggests some Group 3 PH patients may not be receiving guideline-recommended treatment.Electronic supplementary materialThe online version of this article (doi:10.1186/s12890-017-0399-1) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Studies have found significant healthcare resource utilization and economic burdens associated with WHO Group 1 PH (pulmonary arterial hypertension, PAH) and Group 4 PH (chronic thromboembolic pulmonary hypertension, CTEPH) [9–16]. However, there is no similar study for Group 3 PH patients as a whole in the US medical literature.…”

Section: Introductionmentioning

confidence: 99%

Healthcare burden of pulmonary hypertension owing to lung disease and/or hypoxia

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Sildenafil was reported to be cost-effective and associated with lower costs and higher efficacy. (9) In our institution, the cost of PDE5 inhibitor therapy is estimated to be about SGD 500-1,000 per patient per month prior to funding. For patients on combination therapy, pharmacy costs are cumulative.…”

Section: Discussionmentioning

confidence: 99%

Help-seeking patterns and funding strategies in patients with pulmonary arterial hypertension on phosphodiesterase-5 inhibitors: an orphan disease with effective but costly treatment

Lim¹,

Maaroof²,

Low³

et al. 2021

smedj

View full text Add to dashboard Cite

show abstract

“…The economic burden of patients with PAH is noteworthy. Doubtless, the cost for drugs represents the main determinant of the whole expenditure, although the indirect costs for the treatment of patients with PAH are not clearly defined, as suggested by recent surveys (91,92). These reviews showed that the health care costs for treating PAH in USA varied widely from 2,476$ to 11,875$ per patient per month.…”

Section: Economical Sustainability Of Rehabilitation Programs In Pahmentioning

confidence: 99%

Exercise training in pulmonary arterial hypertension

Vecchia

Bussotti

2018

J. Thorac. Dis.

View full text Add to dashboard Cite

Pulmonary arterial hypertension (PAH) is characterized by a continuous increase in pre-capillary pulmonary vascular resistance (PVR) with a progressive reduction of cardiac output (CO). Similar to what occurs in left heart failure (HF), this represents the initial phase of a syndrome characterized by the progressive development of dyspnea and fatigue with increasing deterioration of exercise tolerance. Although the therapies introduced in the last two decades have determined a significant improvement of the clinical conditions of PAH patients, they have a little impact on exercise capacity and prognosis. However, as previously demonstrated for HF, recent pilot studies have reported that physical and respiratory rehabilitation may have a specific role in the management of PAH. Despite potential risks, so far all studies agree that exercise training (ET) improves exercise capacity, quality of life (QoL), muscle function and pulmonary circulation. We will review the pathophysiological mechanisms underlying the functional incompetence of PAH patients, the effects of ET on clinical and functional parameters, the selection criteria for inclusion of patients in a training program, the suggested monitoring of beneficial effects or possible side effects induced by ET. Finally, we discuss of the possible exercise induced amelioration of prognosis in PAH.

show abstract

Systematic Review of the Economic Burden of Pulmonary Arterial Hypertension

Abstract: The economic burden of patients with PAH is substantial, while the paucity of comprehensive country-specific evidence in this area and the lack of reports on indirect costs of PAH warrant researchers' concern, especially in China.

Cited by 29 publications

References 56 publications

Healthcare burden of pulmonary hypertension owing to lung disease and/or hypoxia

Healthcare burden of pulmonary hypertension owing to lung disease and/or hypoxia

Help-seeking patterns and funding strategies in patients with pulmonary arterial hypertension on phosphodiesterase-5 inhibitors: an orphan disease with effective but costly treatment

Exercise training in pulmonary arterial hypertension

Contact Info

Product

Resources

About